Immune therapies of autoimmune diseases: are we approaching a real cure?

Current Opinion in Immunology

Volumn 18, Issue 6, 2006, Pages 710-717

  Chatenoud, Lucienne ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; AUTOANTIGEN; BASILIXIMAB; BELATACEPT; BG 9588; CD20 ANTIBODY; CD3 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; COLLAGEN; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON ANTIBODY; IDEC 131; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INSULIN; LENERCEPT; METHOTREXATE; MYELIN; NATALIZUMAB; OKT 4; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; CROHN DISEASE; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENTERITIS; GASTROINTESTINAL SYMPTOM; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN CELL CULTURE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LUPUS ERYTHEMATOSUS; LYMPHOMA; MAINTENANCE THERAPY; MITOGENICITY; MULTIPLE SCLEROSIS; NONHUMAN; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REPEAT PROCEDURE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TARGET CELL; TUBERCULOSIS; UVEITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY;

EID: 33750390154     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.09.004     Document Type: Review

References (96)

1. Snowden J.A., Passweg J., Moore J.J., Milliken S., Cannell P., Van Laar J., Verburg R., Szer J., Taylor K., Joske D., et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 31 (2004) 482-488
2. Fassas A., Passweg J.R., Anagnostopoulos A., Kazis A., Kozak T., Havrdova E., Carreras E., Graus F., Kashyap A., Openshaw H., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249 (2002) 1088-1097
3. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2 (2002) 364-371
4. Brennan F.M., Chantry D., Jackson A., Maini R., and Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (1989) 244-247
5. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89 (1992) 9784-9788
6. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36 (1993) 1681-1690
7. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
8. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
9. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
10. Bluestone J.A., St Clair E.W., and Turka L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24 (2006) 233-238. This is an interesting critical review on the experimental basis explaining the transfer of CTLA4Ig therapy in autoimmunity and transplantation to the clinic.
11. Williams R.O., Mason L.J., Feldmann M., and Maini R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91 (1994) 2762-2766
12. Rastetter W., Molina A., and White C.A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55 (2004) 477-503
13. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48 (2003) 1484-1492
14. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
15. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46 (2002) 2029-2033
16. Edwards J.C.W., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403. This is a comprehensive review on the rationale that drove biological drugs that target B cells to the clinic.
17. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3 (2003) 123-132
18. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 313 (1985) 337-342
19. Chatenoud L., Baudrihaye M.F., Chkoff N., Kreis H., Goldstein G., and Bach J.F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137 (1986) 830-838
20. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., Gevaert Y., Kreis H., Franchimont P., and Bach J.F. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49 (1990) 697-702
21. Chatenoud L., Ferran C., Reuter A., Legendre C., Gevaert Y., Kreis H., Franchimont P., and Bach J.F. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 320 (1989) 1420-1421
22. Abramowicz D., Schandene L., Goldman M., Crusiaux A., Vereerstraeten P., De Pauw L., Wybran J., Kinnaert P., Dupont E., and Toussaint C. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47 (1989) 606-608
23. Alegre M.L., Peterson L.J., Xu D., Sattar H.A., Jeyarajah D.R., Kowalkowski K., Thistlethwaite J.R., Zivin R.A., Jolliffe L., and Bluestone J.A. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57 (1994) 1537-1543
24. Bolt S., Routledge E., Lloyd I., Chatenoud L., Pope H., Gorman S.D., Clark M., and Waldmann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23 (1993) 403-411
25. Chatenoud L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr Opin Immunol 17 (2005) 632-637
26. H2 cytokines not anergy. Transplantation 67 (1999) 605-613
27. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9 (2003) 1202-1208
28. Chatenoud L., Thervet E., Primo J., and Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91 (1994) 123-127
29. Chatenoud L., Primo J., and Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158 (1997) 2947-2954
30. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174 (2005) 4525-4534. The authors present important experimental work supporting the unique tolerogenic capacity of antibodies to CD3 in overt autoimmunity. Here, parenteral (intravenous) delivery of the antibody for a short course of treatment induced remission of ongoing experimental allergic encephalomyelitis.
31. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 (2002) 1692-1698
32. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., and Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769. This phase I/II study shows that short-term anti-CD3 therapy (using the OKT3 Ala-Ala antibody) administered to patients presenting recent-onset T1D preserves insulin-secreting β cell function for a prolonged period of time after the end of treatment.
33. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005) 2598-2608. Results from this phase II multicentric, double-blind, placebo-controlled trial demonstrates that a six-day treatment with an anti-CD3 antibody (using the ChAglyCD3 antibody) leads not only to sustained effectiveness in terms of preservation of β cell function but also to significant benefit. In fact, the insulin needs are significantly decreased for at least 18 months after the short antibody treatment.
34. Chatenoud L., Salomon B., and Bluestone J.A. Suppressor T cells - they're back and critical for regulation of autoimmunity!. Immunol Rev 182 (2001) 149-163
35. + T cells. Nat Med 12 (2006) 627-635. This work presents a highly original approach that challenges the dogma that therapeutic proteins are ineffective when administered orally because of degradation in the digestive tract. Results show that oral CD3 antibody therapy prevents and reverses ongoing experimental allergic encephalomyelitis.
36. Kaufman D.L., Clare-Salzler M., Tian J., Forsthuber T., Ting G.S.P., Robinson P., Atkinson M.A., Sercarz E.E., Tobin A.J., and Lehmann P.V. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366 (1993) 69-72
37. Tisch R., Yang X.D., Singer S.M., Liblau R.S., Fugger L., and Mcdevitt H.O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366 (1993) 72-75
38. Elias D., Reshef T., Birk O.S., Van Der Zee R., Walker M.D., and Cohen I.R. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 88 (1991) 3088-3091
39. Daniel D., and Wegmann D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 93 (1996) 956-960
40. Harrison L.C., Dempseycollier M., Kramer D.R., and Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 184 (1996) 2167-2174
41. Khoury S.J., Hancock W.W., and Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176 (1992) 1355-1364
42. al-sabbagh A., Miller A., Santos L.M., and Weiner H.L. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 24 (1994) 2104-2109
43. Miller A., Lider O., and Weiner H.L. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 174 (1991) 791-798
44. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., and Hafler D.A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259 (1993) 1321-1324
45. Barnett M.L., Kremer J.M., St Clair E.W., Clegg D.O., Furst D., Weisman M., Fletcher M.J., Chasan-Taber S., Finger E., Morales A., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41 (1998) 290-297
46. Barnett M.L., Combitchi D., and Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 39 (1996) 623-628
47. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., Hafler D.A., and Weiner H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730
48. Nussenblatt R.B., Gery I., Weiner H.L., Ferris F.L., Shiloach J., Remaley N., Perry C., Caspi R.R., Hafler D.A., Foster C.S., et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 123 (1997) 583-592
49. Chaillous L., Lefevre H., Thivolet C., Boitard C., Lahlou N., Atlan-Gepner C., Bouhanick B., Mogenet A., Nicolino M., Carel J.C., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356 (2000) 545-549
50. Ergun-Longmire B., Marker J., Zeidler A., Rapaport R., Raskin P., Bode B., Schatz D., Vargas A., Rogers D., Schwartz S., et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann N Y Acad Sci 1029 (2004) 260-277
51. Raz I., Elias D., Avron A., Tamir M., Metzger M., and Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358 (2001) 1749-1753
52. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346 (2002) 1685-1691
53. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 (2000) 1167-1175
54. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933. A detailed review of more that 3400 patients to evaluate the risk of JC virus-induced progressive multifocal leukoencephalopathy in more than 3000 patients who received natalizumab. Results disclose a risk of about 1 in 1000 patients exposed to the drug for a mean of 17.9 months.
55. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., and von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116 (2006) 1371-1381. An interesting report on the possibility to combine CD3 antibody therapy to the nasal delivery of the candidate autoantigen proinsulin in different experimental models of type 1 diabetes.
56. Moreau T., Thorpe J., Miller D., Moseley I., Hale G., Waldmann H., Clayton D., Wing M., Scolding N., and Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994, 344:486]. Lancet 344 (1994) 298-301
57. Coles A.J., Wing M.G., Smith S., Corradu F., Greer S., Taylor C., Weetman A., Hale G., Chatterjee V.K., Waldmann H., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354 (1999) 1691-1695
58. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., and O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 (2003) 15-23
59. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
60. Furst D.E., Weisman M., Paulus H.E., Bulpitt K., Weinblatt M., Polisson R., Zaug M., Kneer J., Van der Auwera P., and Stevens R.M. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. J Rheumatol 30 (2003) 2123-2126
61. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
62. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J: A long-term, open-label trial of the safety and efficacy of etanercept (ENBREL(R)) in patients with rheumatoid arthritis not treated with other DMARDs (3-year interim report). Ann Rheum Dis 2006, in press.
63. den Broeder A., van de Putte L., Rau R., Schattenkirchner M., Van Riel P., Sander O., Binder C., Fenner H., Bankmann Y., Velagapudi R., et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29 (2002) 2288-2298
64. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., and Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
65. Isaacs J.D., Watts R.A., Hazleman B.L., Hale G., Keogan M.T., Cobbold S.P., and Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340 (1992) 748-752
66. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., Russell A., Dougados M., Emery P., Nuamah I.F., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
67. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., Birbara C., Box J., Natarajan K., Nuamah I., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123
68. Moreland L.W., Alten R., Van den Bosch F., Appelboom T., Leon M., Emery P., Cohen S., Luggen M., Shergy W., Nuamah I., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 (2002) 1470-1479
69. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., Modafferi D., Poulakos J., and Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48 (2003) 927-934
70. Fleischmann R.M., Tesser J., Schiff M., Schechtman J., Burmester G.R., Bennett R., Modafferi D., Zhou L., Bell D., and Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1006-1012
71. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., and Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
72. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., van Vollenhoven R.F., Li N.F., Agarwal S., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
73. Sigidin Y.A., Loukina G.V., Skurkovich B., and Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 30 (2001) 203-207
74. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342 (2000) 763-769
75. Verbsky J.W., and White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31 (2004) 2071-2075
76. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44 (2005) 1542-1545
77. Looney R.J., Anolik J., and Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 13 (2004) 381-390
78. Ostendorf B., Iking-Konert C., Kurz K., Jung G., Sander O., and Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64 (2005) 630-633
79. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., and Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
80. Davis Jr. J.C., Totoritis M.C., Rosenberg J., Sklenar T.A., and Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 28 (2001) 95-101
81. Kalunian K.C., Davis Jr. J.C., Merrill J.T., Totoritis M.C., and Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 3251-3258
82. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
83. Utset T.O., Auger J.A., Peace D., Zivin R.A., Xu D., Jolliffe L., Alegre M.L., Bluestone J.A., and Clark M.R. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29 (2002) 1907-1913
84. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., Li S., Dooley L.T., and Griffiths C.E. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
85. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., and Griffiths C.E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
86. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
87. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 (1999) 1243-1252
88. Menter A., Kosinski M., Bresnahan B.W., Papp K.A., and Ware Jr. J.E. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 3 (2004) 27-38
89. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M: Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials: part I. J Cutan Med Surg 2006, in press.
90. Mease P.J. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 5 (2005) 1491-1504
91. Mathieson P.W., Cobbold S.P., Hale G., Clark M.R., Oliveira D.B., Lockwood C.M., and Waldmann H. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 323 (1990) 250-254
92. Lockwood C.M., Thiru S., Isaacs J.D., Hale G., and Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341 (1993) 1620-1622
93. Stasi R, Stipa E, Poeta GD, Amadori S, Newland AC, Provan D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab, Rheumatology (Oxford) 2006, in press.
94. Nussenblatt R.B. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int Rev Immunol 21 (2002) 273-289
95. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
96. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., and Donoghue S. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32